Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Fiche publication

Date publication

septembre 2022

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Olivera PA, Lasa JS, Zubiaurre I, Jairath V, Abreu MT, Rubin DT, Reinisch W, Magro F, Rahier JF, Danese S, Rabaud C, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36087107

Résumé

Advanced therapies for inflammatory bowel disease (IBD) could potentially lead to a state of immunosuppression with an increased risk of opportunistic infections (OIs). We aimed to update on the incidence of OIs among adult IBD patients in randomized controlled trials (RCTs) of approved biologics and small-molecule drugs (SMDs). Also, we aim to describe OIs definitions utilized in RCTs, to ultimately propose a standardized definition.